Results 41 to 50 of about 37,136 (206)

Intravenous iloprost in the combination therapy of vascular disorders in patients with systemic connective tissue diseases

open access: yesСовременная ревматология, 2013
Systemic connective tissue diseases, systemic scleroderma in particular, constitute a group of diseases in which vascular disorders underlying diverse clinical manifestations are one of the pathogenetic components.
Aleksandr Vitalyevich Volkov   +1 more
doaj   +1 more source

Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey

open access: yesArthritis Care &Research, EarlyView.
Objective Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc ...
Sabrina Hoa   +3 more
wiley   +1 more source

SCLERODERMA NEPHROPATHY: UNSOLVED PROBLEMS

open access: yesJuvenis Scientia, 2021
Kidney injury is a common pathology in the group of patients with systemic sclerosis. At least half of the patients show histological signs of it. Acute condition is known as scleroderma renal crisis.
I. E. Bulavko   +3 more
doaj   +1 more source

Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?

open access: yesArthritis Care &Research, Accepted Article.
Objective The objective is to describe and compare demographic, clinical and serological characteristics of systemic sclerosis (SSc) patients according to ethnic background. Methods Participants enrolled in the Canadian Scleroderma Research Group cohort who self‐identified to a single ethnicity group were included.
Danick Goulet   +33 more
wiley   +1 more source

Optimal management strategies for paediatric morphea – insights from a case series

open access: yesPediatria Polska
Juvenile localized scleroderma, or morphea, is a rare chronic inflammatory disease primarily affecting the skin and subcutaneous tissue. Treatment options for paediatric cases are diverse, with a lack of standardised guidelines.
Kinga Łagosz   +6 more
doaj   +1 more source

Immunologic and nonimmunologic sclerodermal skin conditions - review

open access: yesFrontiers in Immunology, 2023
Scleroderma-like cutaneous lesions have been found in many pathological conditions and they have the clinical appearance of sclerotic or scleroatrophic lesions.
Carmen Bobeica   +17 more
doaj   +1 more source

Time‐Controlled Refrigerated Stem Cell Therapy Mitigates Scleroderma Fibrosis via Modulation of Mitochondrial Autophagy and Gut Metabolism

open access: yesAdvanced Science, EarlyView.
This study established an RT‐MSCs‐based therapeutic approach for scleroderma in mice. RT‐MSCs attenuated fibrosis by regulating mitochondrial autophagy and restored gut microbiota homeostasis. Metabolomic analyses confirmed recovery of key metabolites, and RT‐MSCs demonstrated favorable lesion targeting and safety profiles.
Xue Xia   +5 more
wiley   +1 more source

Pathological Mechanism‐Inspired Biomimetic Nano‐Senotherapy for Reversing Experimental Atherosclerosis in ApoE−/− Mice

open access: yesAdvanced Science, EarlyView.
The biomimetic self‐assembly nanomedicine reversing atherosclerosis via senotherapy strategy. ABSTRACT The greatest challenge in atherosclerosis (AS) management lies in achieving lesion reversal, not merely slowing progression. Senescent cell accumulation—driven by continuous generation and apoptotic resistance—perpetuates plaque pathology and ...
Yuhan Tian   +9 more
wiley   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro   +17 more
wiley   +1 more source

Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A European Multicenter Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Interstitial lung disease (ILD) can occur in association with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV‐ILD) or as an isolated entity with positive ANCA (ANCA‐ILD). However, data on the epidemiology and outcomes of these conditions remain limited.
Aglaia Chalkia   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy